A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs

MLA

Alan F. List, et al. “A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs.” Blood, vol. 118, Nov. 2011, p. 2816. EBSCOhost, https://doi.org/10.1182/blood.v118.21.2816.2816.

APA

Alan F. List, Gary W. Reuther, Kathy L. McGraw, Lori N. Griner, & Joseph O. Johnson. (2011). A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs. Blood, 118, 2816. https://doi.org/10.1182/blood.v118.21.2816.2816

Chicago

Alan F. List, Gary W. Reuther, Kathy L. McGraw, Lori N. Griner, and Joseph O. Johnson. 2011. “A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs.” Blood 118 (November): 2816. doi:10.1182/blood.v118.21.2816.2816.